Four warning letters this year have gone to companies that owe finished dosage form and active pharmaceutical ingredient facility fees.

Eli Lilly soldiers on in emerging markets as a key focus area, as the U.S. firm deals with a steep patent cliff and looks to a diverse pipeline to join its growing animal health business as an earnings driver.